About Aerie Pharmaceuticals (NASDAQ:AERI)
Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The company's advanced-stage product candidate is Roclatan, a once-daily eye drop to reduce IOP to treat patients with open-angle glaucoma and ocular hypertension. Aerie Pharmaceuticals, Inc. has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AERI
CUSIPN/A
Phone919-237-5300
Debt
Debt-to-Equity Ratio0.91%
Current Ratio10.09%
Quick Ratio10.09%
Price-To-Earnings
Trailing P/E Ratio-15.92
Forward P/E Ratio-14.82
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$3.60 per share
Price / Book14.90
Profitability
EPS (Most Recent Fiscal Year)($3.37)
Net Income$-145,100,000.00
Net MarginsN/A
Return on Equity-97.23%
Return on Assets-47.73%
Miscellaneous
Employees160
Outstanding Shares39,490,000
Aerie Pharmaceuticals (NASDAQ:AERI) Frequently Asked Questions
What is Aerie Pharmaceuticals' stock symbol?
Aerie Pharmaceuticals trades on the NASDAQ under the ticker symbol "AERI."
How were Aerie Pharmaceuticals' earnings last quarter?
Aerie Pharmaceuticals (NASDAQ:AERI) released its earnings results on Wednesday, February, 28th. The company reported ($1.38) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($1.21) by $0.17. View Aerie Pharmaceuticals' Earnings History.
What price target have analysts set for AERI?
11 brokers have issued 1-year target prices for Aerie Pharmaceuticals' stock. Their predictions range from $68.00 to $100.00. On average, they anticipate Aerie Pharmaceuticals' share price to reach $79.9091 in the next year. View Analyst Ratings for Aerie Pharmaceuticals.
What are Wall Street analysts saying about Aerie Pharmaceuticals stock?
Here are some recent quotes from research analysts about Aerie Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Aerie received a significant boost with the recent approval of lead drug Rhopressa. The approval came ahead of the PDUFA date. Meanwhile, Aerie is also evaluating Roclatan, a once-daily, quadruple action fixed-dose combination of Rhopressa and Xalatan. Aerie’s shares have outperformed the industry in the last twelve months. However, Rhopressa faces stiff competition from established branded and generic pharmaceutical companies, such as Novartis’ Simbrinza and Travtan, and Allergan’s Lumigan, as well as other smaller biotechnology and pharmaceutical companies. Valeant Pharmaceutical’s Vyzulta is also approved for open-angle glaucoma or ocular hypertension. Rhopressa will face a tough time in gaining market share due to competition from these products. Any approval delays for Roclatan like Rhopressa will be detrimental to the company's growth prospects." (4/17/2018)
- 2. Mizuho analysts commented, "We hosted investor meetings with Aerie management on January 25. Key points that were discussed: 1) Recent capital raise; 2) Readiness for commercialization; and 3) 2018 guidance. We feel confident in management’s abilities with respect to commercial execution as well as maximization of shareholder value should a take-out happen." (1/29/2018)
Who are some of Aerie Pharmaceuticals' key competitors?
Some companies that are related to Aerie Pharmaceuticals include Spark Therapeutics (ONCE), arGEN-X BV (ARGX), China Biologic Products (CBPO), Halozyme Therapeutics (HALO), CRISPR Therapeutics (CRSP), Denali Therapeutics (DNLI), Sangamo Therapeutics (SGMO), Repligen (RGEN), Acceleron Pharma (XLRN), Editas Medicine (EDIT), Momenta Pharmaceuticals (MNTA), Atara Biotherapeutics (ATRA), Audentes Therapeutics (BOLD), DBV Technologies (DBVT), Iovance Biotherapeutics (IOVA), REGENXBIO (RGNX), Cellectis (CLLS) and Adaptimmune Therapeutics (ADAP).
Who are Aerie Pharmaceuticals' key executives?
Aerie Pharmaceuticals' management team includes the folowing people:
- Dr. Vincente J. Anido Jr., Ph.D., Chairman & CEO (Age 65)
- Mr. Thomas A. Mitro, Pres & COO (Age 60)
- Mr. Richard James Rubino CPA, CFO & Sec. (Age 60)
- Dr. Casey C. Kopczynski Ph.D., Co-Founder & Chief Scientific Officer (Age 57)
- Ms. Jessica Crespo CPA, Director of Accounting
Has Aerie Pharmaceuticals been receiving favorable news coverage?
Media coverage about AERI stock has trended positive this week, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Aerie Pharmaceuticals earned a daily sentiment score of 0.26 on Accern's scale. They also assigned press coverage about the company an impact score of 47.44 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term.
How do I buy shares of Aerie Pharmaceuticals?
Shares of AERI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aerie Pharmaceuticals' stock price today?
One share of AERI stock can currently be purchased for approximately $53.65.
How big of a company is Aerie Pharmaceuticals?
Aerie Pharmaceuticals has a market capitalization of $2.12 billion. The company earns $-145,100,000.00 in net income (profit) each year or ($3.37) on an earnings per share basis. Aerie Pharmaceuticals employs 160 workers across the globe.
How can I contact Aerie Pharmaceuticals?
Aerie Pharmaceuticals' mailing address is 4301 Emperor Boulevard Suite 400, North Carolina NC, 27703. The company can be reached via phone at 919-237-5300 or via email at [email protected]
MarketBeat Community Rating for Aerie Pharmaceuticals (AERI)
MarketBeat's community ratings are surveys of what our community members think about Aerie Pharmaceuticals and other stocks. Vote "Outperform" if you believe AERI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AERI will underperform the S&P 500 over the long term. You may vote once every thirty days.
Aerie Pharmaceuticals (NASDAQ:AERI) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
11 Wall Street analysts have issued ratings and price targets for Aerie Pharmaceuticals in the last 12 months. Their average twelve-month price target is $79.9091, suggesting that the stock has a possible upside of 48.95%. The high price target for AERI is $100.00 and the low price target for AERI is $68.00. There are currently 11 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 2.92 | 2.92 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $79.9091 | $79.9091 | $72.4615 | $70.00 |
| Price Target Upside: | 48.95% upside | 44.76% upside | 24.29% upside | 10.58% upside |
Aerie Pharmaceuticals (NASDAQ:AERI) Consensus Price Target History
Aerie Pharmaceuticals (NASDAQ:AERI) Analyst Ratings History
Show:
(Data available from 4/22/2016 forward)
Aerie Pharmaceuticals (NASDAQ:AERI) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Aerie Pharmaceuticals (NASDAQ AERI) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 9.36%
Institutional Ownership Percentage: 96.96%
Aerie Pharmaceuticals (NASDAQ AERI) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/26/2017 | Foresite Capital Fund Ii, L.P. | Major Shareholder | Sell | 20,000 | $55.95 | $1,119,000.00 | |  |
| 4/19/2017 | Gerald D Cagle | Director | Buy | 2,000 | $41.70 | $83,400.00 | 10,900 | |
| 2/15/2017 | Geoffrey M Duyk | Director | Sell | 41,591 | $46.63 | $1,939,388.33 | 10,067 | |
| 10/6/2016 | Foresite Capital Fund Ii, L.P. | Major Shareholder | Sell | 50,000 | $40.34 | $2,017,000.00 | | |
| 7/22/2016 | Foresite Capital Fund Ii, L.P. | Major Shareholder | Buy | 250,000 | $17.50 | $4,375,000.00 | | |
| 4/15/2015 | Anand Mehra | Director | Sell | 425,000 | $33.64 | $14,297,000.00 | | |
| 1/8/2015 | Lifesciences Ii L.P. Clarus | Major Shareholder | Sell | 175,000 | $31.11 | $5,444,250.00 | | |
| 1/5/2015 | Lifesciences Ii L.P. Clarus | Major Shareholder | Sell | 23,620 | $30.86 | $728,913.20 | | |
| 12/29/2014 | Lifesciences Ii L.P. Clarus | Major Shareholder | Sell | 80,724 | $30.05 | $2,425,756.20 | | |
| 12/23/2014 | Lifesciences Ii L.P. Clarus | Major Shareholder | Sell | 49,704 | $30.36 | $1,509,013.44 | | |
| 12/22/2014 | Lifesciences Ii L.P. Clarus | Major Shareholder | Sell | 49,441 | $30.36 | $1,501,028.76 | | |
| 11/25/2014 | Anand Mehra | Director | Sell | 800,000 | $26.00 | $20,800,000.00 | | |
| 11/25/2014 | Group Holdings (Sbs) Advis Tpg | Insider | Sell | 1,300,000 | $25.97 | $33,761,000.00 | | |
| 7/10/2014 | Group Holdings (Sbs) Advis Tpg | Major Shareholder | Sell | 1,000,000 | $25.17 | $25,170,000.00 | | |
| 7/9/2014 | Group Holdings (Sbs) Advis Tpg | Major Shareholder | Sell | 500,000 | $25.05 | $12,525,000.00 | | |
| 5/22/2014 | Anand Mehra | Director | Sell | 323,932 | $16.00 | $5,182,912.00 | | |
| 5/22/2014 | Iv L.P. Acp | Major Shareholder | Sell | 300,000 | $16.00 | $4,800,000.00 | | |
| 5/16/2014 | Gerald Cagle | Director | Buy | 1,854 | $15.07 | $27,939.78 | 1,854 | |
| 10/30/2013 | Brian Levy | Insider | Buy | 6,000 | $10.00 | $60,000.00 | | |
| 10/30/2013 | Iv L.P. Acp | Major Shareholder | Buy | 110,000 | $10.00 | $1,100,000.00 | | |
| 10/30/2013 | Richard J Rubino | CFO | Buy | 10,000 | $10.00 | $100,000.00 | | |
| 10/30/2013 | Thomas A Mitro | COO | Buy | 5,000 | $10.00 | $50,000.00 | | |
| 10/30/2013 | Vicente Anido Jr | CEO | Buy | 28,000 | $10.00 | $280,000.00 | | |
| 10/25/2013 | Anand Mehra | Director | Buy | 285,000 | $10.00 | $2,850,000.00 | | |
| 10/25/2013 | Lifesciences Ii L.P. Clarus | Major Shareholder | Buy | 321,000 | $10.00 | $3,210,000.00 | | |
(Data available from 1/1/2013 forward)
Aerie Pharmaceuticals (NASDAQ AERI) News Headlines
| Source: |
|
Aerie Pharmaceuticals (NASDAQ:AERI) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Aerie Pharmaceuticals (NASDAQ:AERI) Income Statement, Balance Sheet and Cash Flow Statement
Aerie Pharmaceuticals (NASDAQ AERI) Stock Chart for Sunday, April, 22, 2018
Loading chart…
